Section Arrow
AGIO.NASDAQ
- Agios Pharmaceuticals
Quotes are at least 15-min delayed:2024/05/16 19:21 EDT
Last
 35
-0.18 (-0.51%)
Day High 
35.2 
Prev. Close
35.18 
1-M High
35.48 
Volume 
360.18K 
Bid
34.77
Ask
35.37
Day Low
34.82 
Open
35.16 
1-M Low
28.71 
Market Cap 
2.00B 
Currency USD 
P/E -- 
%Yield
10-SMA 33.64 
20-SMA 32.56 
50-SMA 30.78 
52-W High 35.5 
52-W Low 19.795 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-6.31/-6.31
Enterprise Value
2.05B
Balance Sheet
Book Value Per Share
13.10
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
26.82M
Operating Revenue Per Share
0.42
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
SCPXScorpius Holdings0.1001+0.0224+28.83%-- 
DNAGinkgo Bioworks Holdings0.839-0.0001-0.01%-- 
NBYNovaBay Pharmaceuticals0.12+0.0155+14.83%-- 
JAGXJaguar Health0.2867+0.0316+12.39%-- 
NVAXNovavax14.4+1.5+11.63%-- 
Quotes are at least 15-min delayed:2024/05/16 19:21 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Agios Pharmaceuticals Inc is a biopharmaceutical company with a focus on developing treatments geared towards cancer and rare genetic disorders of metabolism. The company's primary focus is to develop potentially transformative small-molecule medicines. The clinical development plan for Agios' product candidates includes a precision approach with initial study designs that allow for genetically or biomarker-defined patient populations. The company seeks the potential for proof of concept early in clinical development, along with any potential for accelerated approval.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.